The upcoming antitrust trial over Cephalon’s alleged reverse-payment settlements with generic drug companies needs to be bifurcated at the liability phase, a federal judge has ruled.
U.S. District Court Judge Mitchell Goldberg of the Eastern District of Pennsylvania determined that the liability portion of the trial will need to be split into violation and causation phases in order to allow jurors to hear key evidence about the validity of the pharmaceutical patent underlying the case without prejudicing the defendants.
